Compounds > mefloquine hydrochloride

mefloquine hydrochloride and atovaquone

mefloquine hydrochloride has been researched along with atovaquone in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (50.00)29.6817
2010's4 (40.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Jomaa, H; Mitsch, A; Schlitzer, M; Wiesner, J; Wissner, P1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Baniecki, ML; Clardy, J; Wirth, DF1
Bertaux, L; Bogreau, H; Bouchiba, H; Garnotel, E; Kraemer, P; Parzy, D; Pradines, B; Rogier, C; Savini, H; Simon, F1
Almeras, L; Amalvict, R; Baret, E; Briolant, S; Fusaï, T; Henry, M; Parquet, V; Pradines, B; Rogier, C; Torrentino-Madamet, M1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Biagini, GA; Chandramohanadas, R; Darling, C; DeGrado, WF; Diamond, SL; Fisher, N; Greenbaum, DC; Jing, H; Jo, H; Lucumi, E; Napper, AD; Shone, AE; Ward, SA1
Beck, HP; Brun, R; Cohen, SB; Dartois, V; Dharia, NV; Diagana, TT; Fidock, DA; Goh, A; González-Páez, GE; Jegla, T; Keller, TH; Lakshminarayana, SB; Lee, MC; McNamara, C; Nosten, F; Plouffe, DM; Renia, L; Rottmann, M; Russell, B; Schmitt, EK; Seitz, P; Spencer, KR; Suwanarusk, R; Tan, J; Winzeler, EA; Yeung, BK; Zou, B1
Bathurst, I; Buckner, FS; Burrows, J; Charman, SA; Charman, WN; Creason, S; Deng, X; El Mazouni, F; Floyd, DM; Gujjar, R; Matthews, D; Phillips, MA; Rathod, PK; Shackleford, DM; White, J; White, KL1

Other Studies

10 other study(ies) available for mefloquine hydrochloride and atovaquone

ArticleYear
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Structure-activity relationships of novel anti-malarial agents. Part 2: cinnamic acid derivatives.
    Bioorganic & medicinal chemistry letters, 2001, Feb-12, Volume: 11, Issue:3

    Topics: Animals; Antimalarials; Cinnamates; Combinatorial Chemistry Techniques; Inhibitory Concentration 50; Microbial Sensitivity Tests; Plasmodium falciparum; Structure-Activity Relationship

2001
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
High-throughput Plasmodium falciparum growth assay for malaria drug discovery.
    Antimicrobial agents and chemotherapy, 2007, Volume: 51, Issue:2

    Topics: Animals; Biological Assay; Child, Preschool; DNA, Protozoan; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Female; Humans; Indoles; Malaria, Falciparum; Parasitic Sensitivity Tests; Plasmodium falciparum; Pregnancy

2007
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
    Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:6

    Topics: Animals; Antimalarials; Atovaquone; Comoros; Drug Resistance; France; Genotype; Humans; Malaria, Falciparum; Male; Parasitic Sensitivity Tests; Plasmodium falciparum; Proguanil; Travel; Treatment Failure

2008
Atorvastatin is a promising partner for antimalarial drugs in treatment of Plasmodium falciparum malaria.
    Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:6

    Topics: Animals; Antimalarials; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Plasmodium falciparum; Pyrroles

2009
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:9

    Topics: Animals; Antimalarials; Drug Resistance, Multiple; Molecular Structure; Parasitic Sensitivity Tests; Plasmodium falciparum

2010
Spiroindolones, a potent compound class for the treatment of malaria.
    Science (New York, N.Y.), 2010, Sep-03, Volume: 329, Issue:5996

    Topics: Adenosine Triphosphatases; Animals; Antimalarials; Cell Line; Drug Discovery; Drug Resistance; Erythrocytes; Female; Genes, Protozoan; Humans; Indoles; Malaria; Male; Mice; Models, Molecular; Mutant Proteins; Mutation; Parasitic Sensitivity Tests; Plasmodium berghei; Plasmodium falciparum; Plasmodium vivax; Protein Synthesis Inhibitors; Protozoan Proteins; Rats; Rats, Wistar; Spiro Compounds

2010
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.
    Journal of medicinal chemistry, 2011, Jun-09, Volume: 54, Issue:11

    Topics: Animals; Antimalarials; Dihydroorotate Dehydrogenase; Disease Models, Animal; Drug Design; Drug Discovery; Enzyme Inhibitors; Humans; Malaria; Mice; Microsomes, Liver; Molecular Structure; Oxidoreductases Acting on CH-CH Group Donors; Plasmodium berghei; Plasmodium falciparum; Protein Binding; Pyrimidines; Solubility; Structure-Activity Relationship; Triazoles

2011